Newsfeeds - Spark Newswire

1 minute read

Uncategorized

Unity Biotechnology has received a decision to grant European patent number EP3787626 titled “PHOSPHONAMIDATES THAT ARE BCL FAMILY ANTAGONISTS FOR USE IN CLINICAL MANAGEMENT OF CONDITIONS CAUSED OR MEDIATED BY SENESCENT CELLS AND FOR TREATING CANCER

By Charles Gross

Today, 7:23 PM

https://register.epo.org/application?number=EP19797087

16 minute read

Uncategorized

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 7:23 PM

On Wednesday, 283 companies set new 52-week lows.

1 minute read

Uncategorized

UNITY Biotechnology Announces 24-Week Data From Phase 2 BEHOLD Study Of UBX1325 In Patients With Diabetic Macular Edema

By Benzinga Newsdesk

Today, 7:23 PM

A single injection of UBX1325 led to a statistically significant and clinically relevant improvement in Best Corrected Visual Acuity (BCVA) of 7.6 ETDRS letters at 24 weeks compared to sham treatment UBX1325

23 minute read

Uncategorized

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 7:23 PM

On Monday, 413 companies reached new 52-week lows.

1 minute read

Uncategorized

Unity Biotechnology Files For Mixed-Securities Shelf Offering Of Up To $250M

By Michael Horton

Today, 7:23 PM

-SEC Filing

30 minute read

Uncategorized

Stocks That Hit 52-Week Lows On Wednesday

By Benzinga Insights

Today, 7:23 PM

During Wednesday's trading, 517 companies set new 52-week lows.

47 minute read

Uncategorized

Stocks That Hit 52-Week Lows On Tuesday

By Benzinga Insights

Today, 7:23 PM

On Tuesday, 838 companies hit new 52-week lows.

3 minute read

Uncategorized

UNITY Biotechnology’s Investor And Analyst Day To Highlight UBX1325 Program In Age-Related Diseases Of The Eye October 12

By Benzinga Newsdesk

Today, 7:23 PM

- Presentations from UNITY's leadership team and fireside chat with retina expert Robert B. Bhisitkul, M.D., Ph.D., on Wednesday, October 12 from 8:00 a.m. to 9:30 a.m. ET - SOUTH SAN FRANCISCO, Calif., Oct.